Cogent Biosciences (formerly known as Unum Therapeutics) is a biotechnology company that designs precision therapies to treat genetically driven diseases. It offers bezuclastinib, a tyrosine kinase type III (KIT) inhibitor designed to target exon 17 mutations found within the KIT receptor tyrosine kinase, including KIT D816V. The company also provides Phase 2 clinical trial Apex that evaluates pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.